未知股票 CERO 深 滬
已收盤
--
0.000
NaN.00%
華盛通- 最 高--
- 今 開--
- 成交量 --
- 最 低 --
- 昨 收 --
- 總市值 0
- 52周最高 --
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 總股本 2110.27万
- 歷史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 歷史最低 --
- 每 手 1
- 風險率 111.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Cero Therapeutics Hearing Review Council Issued Decision
BRIEF-Cero Therapeutics Hearing Review Council Issued Decision Feb 3 (Reuters) - CERo Therapeutics Holdings Inc CERO.PK : CERO THERAPEUTICS: HEARING REVIEW COUNCIL ISSUED DECISION AFFIRMING NASDAQ HEARING PANEL'S DECISION TO DELIST COMPANY’S SECURITIES FROM NASDAQ Source text: [ID:n0001213900-26-011
02-04 07:23
CERo Therapeutics Securities Delisted Following Nasdaq Appeal Denial
CERo Therapeutics Holdings ( ($CERO) ) just unveiled an update. On October 29, ...
02-04 06:51
CERo Therapeutics denied Nasdaq listing, seeks OTC markets
Cellular immunotherapy company CERo Therapeutics (CERO) received a determination letter from Nasdaq Hearings Panel that denies the company’s request to continue the listing of its shares of common s...
2025-10-30 13:04
Broadwind Announces Third Quarter 2025 Results Conference Call and Webcast Date
Broadwind announced it will release its third quarter 2025 financial results on November 13, 2025, before the market opens. A conference call will follow at 11:00 a.m. ET to discuss the results, with a live webcast available via the company’s Investor Relations website. Participants can join the teleconference at 877-407-9716, and a replay will be available until November 20, 2025, using the conference ID 13756444. Broadwind is a precision manufa...
2025-10-30 11:00
CERo Therapeutics Announces Receipt of Nasdaq Panel Determination
CERo Therapeutics Holdings, Inc. announced that its shares will be suspended from trading on Nasdaq starting October 31. The company was denied its request to continue listing on Nasdaq due to non-compliance with the $2.5 million stockholders' equity rule. CERo plans to appeal the decision, seek trading on the OTC Markets, and continue clinical operations, including dosing patients in its trials for CER-1236. The company is reviewing its cash res...
2025-10-29 23:22
CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025
South San Francisco, Oct. 15, 2025 - CERo Therapeutics Holdings, Inc. announces that Chief Executive Officer Chris Ehrlich will participate in a stem cell therapy panel at the Maxim Growth Summit in New York City on October 22-23. The event will feature discussions on the future of stem cell therapies, with a focus on the innovative approaches being developed in the biotechnology sector. CERo, a leader in cellular immunotherapy, is advancing next...
2025-10-15 12:30
CERo Therapeutics Enters Securities Purchase Agreement
The latest announcement is out from CERo Therapeutics Holdings ( ($CERO) ). CER...
2025-10-14 21:28
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
2025-10-14 09:56
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target
D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price target.
2025-10-13 22:43
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML
CERo Therapeutics has completed the first cohort of its Phase 1 clinical trial for CER-1236 in acute myeloid leukemia (AML) patients, observing consistent cell expansion without dose-limiting toxicities. The Dose Escalation Safety Committee has approved the initiation of Cohort 2 with an increased starting dose. The company also plans to provide an additional infusion to Cohort 1 patient based on encouraging pharmacokinetic data. CERo emphasizes ...
2025-10-13 12:30
